Abstract
Correction: Twice- or Once-Daily Dosing of Novel Oral Anticoagulants for Stroke Prevention: A Fixed-Effects Meta-Analysis with Predefined Heterogeneity Quality Criteria
Highlights
Copyright: ß 2014 The PLOS ONE Staff
All dose groups: x2 = 19.78, df = 5, p = 0.001, I2 = 75% BID x2 = 1.78, df = 1, p = 0.18, I2 = 44% All dose groups: x2 = 20.43, df = 5, p = 0.001, I2 = 76% BID x2 = 1.31, df = 1, p = 0.25, I2 = 24% All dose groups: x2 = 0.97, df = 5, p = 0.96, I2 = 0% BID x2 = 0.02, df = 1, p = 0.90, I2 = 0% All dose groups: x2 = 17.41, df = 5, p = 0.004, I2 = 71% BID x2 = 0.92, df = 1, p = 0.34, I2 = 0% All dose groups: x2 = 71.23, df = 5, p = 0.00001, I2 = 93% BID x2 = 10.02, df = 1, p = 0.002, I2 = 90%
*Dose with most pronounced efficacy result: dabigatran 150 mg BID, apixaban 5/2.5 mg BID, rivaroxaban 20/15 mg QD, and edoxaban 60/30 mg QD
Summary
Stroke and systemic embolism Ischemic/unspecified stroke All-cause mortality Intracranial hemorrhage Major bleeding event
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
